Baron Global Advantage Fund (BGAFX)

Portfolio Management

Alex Umansky

Fund Manager since 2012

View All Commentary by Alex

Fund Description

Baron Global Advantage Fund invests in growth companies of all sizes anywhere.


Portfolio Commentary

Retail Performance

Review and Outlook (for quarter ended 6/30/2016)

The Review and Outlook for period ending June 30, 2016 is not yet available

Top Contributors/Detractors to Performance

Contributors (for quarter ended 6/30/2016)
  • Shares of, Inc., the world’s largest retailer and cloud services provider, rose in Q2 on strong revenue growth and improving margins in the core business. Amazon’s other major business segment, Amazon Web Services (AWS) continues to gain traction with enterprise customers, and had another strong quarter of growth. Over time, we expect AWS to be the larger contributor to value creation. Amazon continues to invest in new and potentially large business segments such as e-finance, business supplies, and apparel.

  • TAL Education Group is a leading Chinese K-12 tutoring company, operating over 360 learning centers in 24 cities. Shares of TAL appreciated in Q2, driven by growth in enrollments of over 55%. We see significant opportunity for growth as TAL expands existing learning centers, opens new learning centers in existing cities, and enters new cities, while generating strong cash flow. The new hybrid class initiative in which classes are webcast to distant learning centers has the potential to improve teacher utilization and increase margins.

  • Glaukos Corporation is developing products to drain intraocular (eye) fluid to relieve the symptoms of glaucoma and delay/prevent blindness. Improved sales of its lead product, iStent, drove strong revenue growth in the quarter. We see several drivers of future growth. iStent offers an alternative to daily eye drops, which require long-term patient compliance. A recent real-world study produced good results that exceeded clinical trial results. The company is also planning to expand internationally. 

Detractors (for quarter ended 6/30/2016)
  • Pacira Pharmaceuticals, Inc., a pharmaceutical that makes pain control drug EXPAREL, had a watershed event in mid-December 2015 when it won a favorable settlement of a marketing dispute with the FDA. Pacira received broad, definitive labeling for many major surgical uses. Shares peaked earlier in 2016, but have since dropped due to broader concerns in the pharma sector as well as growth guidance biased toward the second half of 2016. We believe Pacira has the potential for 25-35% top line growth for years to come.

  • Alphabet Inc. is the world’s largest search and online advertising-related company. Shares of Alphabet were driven down by Q1 results that missed Street expectations. We believe that while desktop search is becoming a more mature business for the company, Alphabet is well positioned to benefit from substantial growth in mobile and online video advertising.

  • EPAM Systems, Inc. provides outsourced software development using highly skilled, low-cost employees primarily in Eastern Europe and Russia. EPAM reported strong quarterly results that exceeded management guidance, with 32% revenue growth and 26% EPS growth. However, shares fell following “Brexit” as EPAM has meaningful exposure to European customers (36% of revenue), especially European banks whose IT budgets could come under pressure. We believe customer demand will remain robust and that EPAM has a long runway for growth in a large market.

Quarterly Attribution Analysis (for quarter ended 6/30/2016)

The Quarterly Attribution Analysis for period ending June 30, 2016 is not yet available

Back to Top

Invest In Baron Funds Today